A vaccine from Johnson & Johnson which could be delivered to the UK in the second half of this year is 66% effective against Covid-19, trial results show.
The single-shot vaccine, which has been developed by Johnson & Johnson’s pharmaceutical arm Janssen, is 66% effective overall at preventing moderate to severe Covid-19 28 days after vaccination.
The firm said the jab was 85% effective in preventing severe disease “and demonstrated complete protection against Covid-19-related hospitalisation and death as of day 28”.
This means that one month after vaccination, no one who received the vaccine was admitted to hospital or died, regardless of which strain of coronavirus they were exposed to.
If this jab is approved this could significantly bolster our vaccination programme, especially as a single-dose vaccine. Once the full data has been submitted to the Medicines & Healthcare products Regulatory Agency, they will consider the evidence to determine whether the vaccine meets robust standards of safety, effectiveness & quality. We re rolling-out vaccines as quickly as possible across the UK, with more than 7.4 million people given their first dose so far.
Paul Stoffels, chief scientific officer at Johnson & Johnson, said: The potential to significantly reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with just one immunisation, is a critical component of the global public health response.
A vaccine from Johnson & Johnson which could be delivered to the UK in the second half of this year is 66% effective against Covid-19, trial results show.
The single-shot vaccine, which has been developed by Johnson & Johnson’s pharmaceutical arm Janssen, is 66% effective overall at preventing moderate to severe Covid-19 28 days after vaccination.
The firm said the jab was 85% effective in preventing severe disease “and demonstrated complete protection against Covid-19-related hospitalisation and death as of day 28”.
This means that one month after vaccination, no one who received the vaccine was admitted to hospital or died, regardless of which strain of coronavirus they were exposed to.
UK could get Novavax vaccine by SUMMER: Jab which is 89% effective against Kent variant and can be adapted to new strains could be submitted for approval in two weeks and in Britain within months, clinical trial chief reveals
Trial results showed it was 89.3 per cent effective against coronavirus and the Kent variant of the virus
And 60 per cent effective against South African strain which has sparked concern among many scientists
Professor Paul Heath, who led trials, said today they may be able to conclude their trial within two weeks
He added results against the South African strain were really good and may be replicated by other jabs
A vaccine from Johnson & Johnson which could be delivered to the UK in the second half of this year is 66% effective against Covid-19, trial results show.
The single-shot vaccine, which has been developed by Johnson & Johnson’s pharmaceutical arm Janssen, is 66% effective overall at preventing moderate to severe Covid-19 28 days after vaccination.
The firm said the jab was 85% effective in preventing severe disease “and demonstrated complete protection against Covid-19-related hospitalisation and death as of day 28”.
This means that one month after vaccination, no one who received the vaccine was admitted to hospital or died, regardless of which strain of coronavirus they were exposed to.